1. Cost-effectiveness of duloxetine for knee OA subjects: the role of pain severity
- Author
-
David J. Hunter, Elena Losina, Edward H. Yelin, Jeffrey N. Katz, Robert R. Edwards, Jamie L. Huizinga, Tuhina Neogi, and James K. Sullivan
- Subjects
0301 basic medicine ,musculoskeletal diseases ,medicine.medical_specialty ,WOMAC ,Cost effectiveness ,Cost-Benefit Analysis ,Total knee replacement ,Biomedical Engineering ,Pain relief ,Osteoarthritis ,Duloxetine Hydrochloride ,Article ,Injections, Intra-Articular ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Rheumatology ,medicine ,Duloxetine ,Humans ,Orthopedics and Sports Medicine ,Computer Simulation ,Arthroplasty, Replacement, Knee ,Glucocorticoids ,health care economics and organizations ,Aged ,Pain Measurement ,030203 arthritis & rheumatology ,Analgesics ,business.industry ,Middle Aged ,Osteoarthritis, Knee ,medicine.disease ,humanities ,Analgesics, Opioid ,030104 developmental biology ,chemistry ,Pain severity ,Physical therapy ,Quality-Adjusted Life Years ,business ,Medical costs - Abstract
OBJECTIVE: Establish the impact of pain severity on the cost-effectiveness of generic duloxetine for knee osteoarthritis (OA) in the United States. DESIGN: We used a validated computer simulation of knee OA to compare usual care (UC) – intra-articular injections, opioids, and total knee replacement (TKR) - to UC preceded by duloxetine in those no longer achieving pain relief from non-steroidal anti-inflammatory drugs (NSAIDs). Outcomes included quality-adjusted life years (QALYs), lifetime medical costs, and incremental cost-effectiveness ratios (ICERs). We considered cohorts with mean ages 57–75 years and Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain 25–55 (0–100, 100-worst). We derived inputs from published data. We discounted costs and benefits 3% annually. We conducted sensitivity analyses of duloxetine efficacy, duration of pain relief, toxicity, and costs. RESULTS: Among younger subjects with severe pain (WOMAC pain=55), duloxetine led to an additional 9.6 QALYs per 1000 subjects (ICER=$88,500/QALY). The likelihood of duloxetine being cost-effective at willingness-to-pay (WTP) thresholds of $50,000/QALY and $100,000/QALY was 40% and 54%. Offering duloxetine to older patients with severe pain led to ICERs >$150,000/QALY. Offering duloxetine to subjects with moderate pain (pain=25) led to ICERs $88,500/QALY.
- Published
- 2020